NEW YORK – Quest Diagnostics and the US Food and Drug Administration announced on Saturday that the company received Emergency Use Authorization from the FDA to for the use of Quest's SARS-CoV-2 RNA test for pool sampling to detect the coronavirus.
The agency reissued an EUA to the Secaucus, New Jersey-based company for the test, which is the first to receive the designation for pooled sampling for COVID-19 testing.